Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Phio Pharmaceuticals Corp PHIO

Healthcare Biotechnology
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or... see more

Recent & Breaking News (NDAQ:PHIO)

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Newsfile July 8, 2024

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Newsfile July 5, 2024

Phio Pharmaceuticals Announces Reverse Stock Split

Newsfile July 2, 2024

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

Newsfile June 18, 2024

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762

Newsfile May 28, 2024

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Newsfile May 23, 2024

Phio Pharmaceuticals Secures New Investor

GlobeNewswire May 17, 2024

Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)

GlobeNewswire May 16, 2024

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

GlobeNewswire May 15, 2024

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

GlobeNewswire May 9, 2024

Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

GlobeNewswire April 30, 2024

Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

GlobeNewswire April 22, 2024

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

GlobeNewswire April 16, 2024

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

GlobeNewswire April 11, 2024

National Spotlight Features Phio's Innovative RNAi Technology Platform

GlobeNewswire April 3, 2024

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

GlobeNewswire April 2, 2024

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

GlobeNewswire March 21, 2024

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

GlobeNewswire March 13, 2024

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders

GlobeNewswire March 6, 2024

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

GlobeNewswire January 31, 2024